US2014206839A1PendingUtilityA1
Cross linked hyaluronic acid-silk and uses thereof
Est. expiryApr 20, 2029(~2.8 yrs left)· nominal 20-yr term from priority
A61P 41/00A61P 43/00A61P 9/06A61L 27/52A61L 27/26A61K 38/1767A61L 27/227A61K 47/42A61Q 19/00A61K 8/64C08B 37/0072A61K 2800/91A61P 23/02A61L 2430/34A61P 17/00A61K 2800/5922A61F 2/12
65
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present specification provides for methods for purifying fibroins, purified fibroins, methods of conjugating biological and synthetic molecules to fibroins, fibroins conjugated to such molecules, methods of making fibroin hydrogels, fibroin hydrogels and fibroin hydrogel formulations useful for a variety of medical uses, including, without limitation uses as bulking agents, tissue space fillers, templates for tissue reconstruction or regeneration, cell culture scaffolds for tissue engineering and for disease models, surface coating to improve medical device function, or drug delivery devices.
Claims
exact text as granted — not AI-modifiedWe claim:
1 . A formulation comprising silk conjugated to hyaluronic acid.
2 . The formulation of claim 1 wherein the silk is silk fibroin or the silk is a silk molecule.
3 . The formulation of claim 2 wherein the hyaluronic acid is covalently attached to the silk.
4 . The formulation of claim 3 wherein the formulation further comprises an amino acid spacer which covalently attaches the hyaluronic acid to the silk.
5 . The formulation of claim 4 wherein the amino acid spacer is selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, and SEQ ID NO: 25.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.